Roche, divarasib, KRAS G12C, non-small cell lung cancer, NSCLC, Krascendo 1, Phase 3 clinical trial, targeted cancer therapy, overall survival, progression-free survival, sotorasib, adagrasib

Basel, Switzerland, October 25, 2026 Roche has announced positive Phase 3 results for divarasib, an investigational next-generation KRAS G12C...